Target family: Polo-like kinase (PLK) family (type: enzyme)
Target: polo like kinase 1

Ligand: BI-2536 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.079999923706055 pIC50
Reference (Journal): BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Published in: Curr Biol

Ligand: BI-2536 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKi
Reference (Journal): Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 2 [PMID: 19097784] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of thiophene inhibitors of polo-like kinase.
Published in: Bioorg Med Chem Lett

Ligand: compound 6 [PMID: 30125504] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Published in: J Med Chem

Ligand: dual BRD4/PLK1 inhibitor 23 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Published in: J Med Chem

Ligand: GSK-461364A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pKi
Reference (Journal): Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Published in: Cancer Res

Ligand: GSK579289A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Published in: Bioorg Med Chem Lett

Ligand: GW853606 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Discovery of thiophene inhibitors of polo-like kinase.
Published in: Bioorg Med Chem Lett

Ligand: MLN0905 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Published in: J Med Chem

Ligand: onvansertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Published in: Bioorg Med Chem Lett

Ligand: plogosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Patent): Pyrimidine derivatives as protein kinase inhibitors

Ligand: Ro3280 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10.050000190734863 pKd
Reference (Journal): Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Published in: Bioorg Med Chem Lett

Ligand: Ro3280 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Published in: Bioorg Med Chem Lett

Ligand: volasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.0600004196167 pIC50
Reference (Journal): Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: WNY0824 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.659999847412109 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Published in: Eur J Med Chem

Ligand: XY-06-007 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.010000228881836 pIC50
Reference (Journal): Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Published in: Eur J Med Chem